| Date |
Acquired company |
Acquiring company |
Amount |
Related |
| 2018-04-16 |
Shire's oncology business (UK-USA) |
Servier (France) |
$2.4 billion (€1.94 billion) |
|
| 2018-02-21 |
Viralytics (Australia) |
Merck&Co (USA - NJ) |
$394 million |
Cancer - Oncology |
| 2018-02-20 |
Clinical Assistance Programs (CAP) (USA - MA) |
Alira Health (France - Germany - Italy - Spain - USA) |
undisclosed |
Technology - Services |
| 2018-02-01 |
Advanced Accelerator Applications (France) |
Novartis (Switzerland) |
$3.9 billion |
Cancer - Oncology |
| 2018-01-29 |
Ablynx (Belgium) |
Sanofi (France) |
€3.9 billion |
Hematological diseases - Inflammatory diseases |
| 2018-01-22 |
Bioverativ (USA - CA) |
Sanofi (France) |
$11.6 billion (€ 9.47 billion) |
Rare diseases - Genetic diseases - Hematological diseases |
| 2018-01-22 |
Juno Therapeutics (USA - WA) |
Celgene (USA _ NJ) |
$9 billion (€ 7.34 billion) |
Cancer - Oncology - Hematological diseases |
| 2018-01-08 |
Ablynx (Belgium) |
Novo Nordisk (Denmark) |
€ 2.6 billion |
Hematological diseases - Inflammatory diseases |
| 2018-01-05 |
Tigenix (Belgium) |
Takeda Pharmaceutical (Japan) |
€ 520 million |
|
| 2017-12-29 |
Sellas Life Sciences (Bermuda) |
Galena BioPharma (USA - OR) |
|
Cancer - Oncology |
| 2017-12-26 |
Sucampo Pharmaceuticals (USA - MA) |
Mallinckrodt (UK) |
$1.2 Billion |
Rare diseases |
| 2017-12-23 |
Discuva (UK) |
Summit (UK) |
£10 million |
Infectious diseases |
| 2017-12-21 |
Ignyta (USA - CA) |
Roche (Switzerland) |
$ 1.7 billion |
Cancer - Oncology |
| 2017-12-21 |
Pasteur Group (Brazil) |
Eurofins Scientific (Luxembourg) |
undisclosed |
Diagnostic |
| 2017-12-20 |
Alizé Pharma (France) |
Millendo Therapeutics (USA - Mich) |
undisclosed |
Endocrine diseases - Hormonal diseases |
| 2017-12-07 |
Cell Design Labs (USA - CA) |
Gilead Sciences (USA - CA) |
$567 million |
Technology - Services - Cancer - Oncology |
| 2017-12-07 |
Eurotrials (Portugal) |
CTI Clinical Trial and Consulting Services (CTI) (USA - KY) |
undisclosed |
|
| 2017-11-07 |
Dimension Therapeutics (USA - MA) |
Ultragenyx Pharmaceuticals (USA - CA) |
$ 151 million |
Rare diseases - Genetic diseases |
| 2017-10-03 |
Kite Pharma (US - CA) |
Gilead Sciences (USA - CA) |
$11.9 billion |
Cancer - Oncology - Cell therapy |
| 2017-10-02 |
RegenxBio (USA - MD) |
Dimension Therapeutics (USA - MA) |
|
Rare diseases - Genetic diseases |
